Investor Presentaiton slide image

Investor Presentaiton

Target protein E3 ligase BMS-986458 is a novel ligand directed degrader (LDD) targeting BCL6 in lymphoma Transformational potential Oral small molecule medicine to treat B cell lymphomas driven by abnormalities in BCL6 signaling pathway. Causal human biology Gain-of-function somatic BCL6 mutations lead to B cell lymphomas and deletion of BCL6 prevents B cell maturation. Naive B cells Healthy, Germinal center Mature B cells Matching modality to mechanism that has exquisite We created a BCL6 LDD selectivity relative to the human proteome -log10 (nominal p-value) Only target degraded BCL6 GSNKAL BCL2CSPTIZE IKZFZFP91 WEE IVDP 4 CHEK1 IKZF3 -4 -2 0 2 4 Log² fold change (vs/ DMSO) Path to clinical proof-of-concept Correlate BCL6 degradation with clinical benefit BCL6 IHC high expression High BCL6 Malignant B cells (e.g., DLBCL) Ill Bristol Myers Squibb™ BCL6 LDD drug Conc. (μM) 100 -20 -10 Plasma conc. -0 10- 10 Tumor conc. -20 1 30 40 50 0.11 -60 0.01 BCL6 levels -70 80 98% 98% 95% 90 ☐ 0.001 -100 -2 Veh 2 4 6 8 10 12 14 16 Sample collection time (h) % BCL6 Degradation in -30% DLBCL Not for Product Promotional Use 39
View entire presentation